Innovent Biologics (OTCMKTS:IVBXF – Get Free Report) is expected to be releasing its results after the market closes on Tuesday, August 25th. Analysts expect the company to announce earnings of $0.0692 per share and revenue of $1.3102 billion for the quarter.
Innovent Biologics Price Performance
IVBXF opened at $11.80 on Monday. Innovent Biologics has a 12 month low of $9.10 and a 12 month high of $15.12. The firm’s fifty day simple moving average is $11.33 and its 200 day simple moving average is $10.88.
About Innovent Biologics
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.
The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).
Read More
- Five stocks we like better than Innovent Biologics
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
